The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery
Abstract
The anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody ipilimumab has been shown to improve survival in patients with metastatic non-CNS melanoma. The purpose of this study was to investigate the efficacy of CTLA-4 inhibitors in the treatment of metastatic melanoma with limited brain metastases treated with stereotactic radiosurgery (SRS). Between January 2008 and June 2011, 58 patients with limited brain metastases from melanoma were treated with SRS with a median dose of 20 Gy delivered to the 50% isodose line (range, 15-20 Gy). In 25 patients, ipilimumab was administered intravenously at a dose of 3 mg/kg over 90 min every 3 weeks for a median of four doses (range, 1-8). Local control (LC), freedom from new brain metastases, and overall survival (OS) were assessed from the date of the SRS procedure. The median LC, freedom from new brain metastases, and OS for the entire group were 8.7, 4.3, and 5.9 months, respectively. The cause of death was CNS progression in all but eight patients. Six-month LC, freedom from new brain metastases, and OS were 65, 35, and 56%, respectively, for those who received ipilimumab and 63, 47, and 46% for those who did not (P=NS). Intracranial hemorrhage was noted in seven patients who received ipilimumab compared with 10 patients who received SRS alone (P=NS). In this retrospective study, administration of ipilimumab neither increased toxicity nor improved intracerebral disease control in patients with limited brain metastases who received SRS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Cited by
Kiess, A. P., Wolchok, J. D., Barker, C. A., Postow, M. A., Tabar, V., Huse, J. T., Chan, T. A., Yamada, Y., & Beal, K. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.01.004 · Cited by 390
Brain metastases: epidemiology
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-811161-1.00002-5 · Cited by 336
Chen, L., Douglass, J., Kleinberg, L., Ye, X., Marciscano, A. E., Forde, P. M., Brahmer, J., Lipson, E., Sharfman, W., Hammers, H., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.11.041 · Cited by 329
Ipilimumab and radiation therapy for melanoma brain metastases
Silk, A. W., Bassetti, M. F., West, B. T., Tsien, C. I., & Lao, C. D. (2013) · Cancer Medicine · doi:10.1002/cam4.140 · Cited by 280
Lehrer, E. J., Peterson, J., Brown, P. D., Sheehan, J. P., Quiñones-Hinojosa, A., Zaorsky, N. G., & Trifiletti, D. M. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.08.025 · Cited by 264
Metadata
- Authors
- Mathew, M., Tam, M., Ott, P. A., Pavlick, A. C., Rush, S. C., Donahue, B. R., Golfinos, J. G., Parker, E. C., Huang, P. P., & Narayana, A.
- Venue
- Melanoma Research
- Published
- 2013-06
- Volume
- 23
- Issue
- 3
- Pages
- 191-195
- ISSN
- 0960-8931 (ISSN-L)
- OpenAlex
- W2007225806
- Cited by
- 178
- References
- 2
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. https://app.cochat.ai/papers/10.1097/cmr.0b013e32835f3d90
- The paper
- Mathew, M., Tam, M., Ott, P. A., Pavlick, A. C., Rush, S. C., Donahue, B. R., Golfinos, J. G., Parker, E. C., Huang, P. P., & Narayana, A. (2013). Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Research. https://doi.org/10.1097/cmr.0b013e32835f3d90
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.